| Trial ID: | L0242 |
| Source ID: | NCT03468556
|
| Associated Drug: |
SNP-610
|
| Title: |
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
|
| Acronym: |
--
|
| Status: |
Not yet recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: SNP-610|Drug: Placebo Oral Tablet
|
| Outcome Measures: |
Alanine aminotransferase|MRI liver FF|Aspartate aminotransferase|Alkaline phosphatase|Gamma-glutamyl transpeptidase|Total bilirubin|Galactose single point|CK-18
|
| Sponsor/Collaborators: |
Sinew Pharma Inc.
|
| Gender: |
All
|
| Age: |
20 Years and older ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
80
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
December 1, 2022
|
| Completion Date: |
December 30, 2023
|
| Results First Posted: |
--
|
| Last Update Posted: |
March 9, 2022
|
| Locations: |
--
|
| URL: |
https://ClinicalTrials.gov/show/NCT03468556
|
